Risk of venous thromboembolism in carriers of factor V Leiden with a concomitant inherited thrombophilic defect:: a retrospective analysis

被引:24
|
作者
Meinardi, JR
Middeldorp, S
de Kam, PJ
Koopman, AMW
van Pampus, ECM
Hamulyák, K
Prins, MH
Büller, HR
van der Meer, J
机构
[1] Univ Hosp, Div Haemostasis Thrombosis & Rheol, NL-9713 GZ Groningen, Netherlands
[2] Univ Hosp, Trial Coordinat Ctr, Groningen, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Ctr Haemostasis Thrombosis Atherosclerosis & Infl, NL-1105 AZ Amsterdam, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands
[5] Univ Hosp, Dept Haematol, Maastricht, Netherlands
关键词
thromboembolism; blood coagulation disorders; activated protein C resistance; factor V;
D O I
10.1097/00001721-200112000-00014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Factor V Leiden is the most common genetic defect associated with venous thromboembolism. Its clinical expression is limited and shows a wide intrafamilial and interfamilial variation, which might be explained by the influence of other genetic risk factors. We retrospectively studied 226 patients with factor V Leiden and documented venous thromboembolism (probands) and 400 first-degree carrier relatives to assess the contribution of concomitant genetic risk factors to the occurrence of venous thromboembolism. The prothrombin G20210A mutation was found in 8.3%, homozygosity of factor V Leiden in 7.2%, and inherited deficiencies of antithrombin, protein C or protein S in 4.7% of symptomatic carriers (probands and relatives), as compared with 6.0, 3.4 and 0.9% of asymptomatic carriers, respectively. The total follow-up time in relatives was 11049 years. Prevalences of venous thromboembolism were 10.8% in single heterozygous factor V Leiden carrier relatives, 16.0% in double-heterozygotes for factor V Leiden and the prothrombin mutation, 36.8% in homozygotes for factor V Leiden, and 40.0% in double-heterozygotes for factor V Leiden and an inherited deficiency of protein C or protein S. Annual incidences in these groups were 0.39, 0.57, 1.41, and 4.76%, respectively. Multivariate analysis showed a small, non-significant additional effect of the prothrombin mutation on the risk of venous thromboembolism in heterozygotes for factor V Leiden [adjusted hazard ratio, 1.3; 95% confidence interval (CI), 0.5-3.8]. This effect was more pronounced for homozygosity of factor V Leiden (adjusted hazard ratio, 3.9; 95% CI, 1.7-9.0) and inherited protein C or protein S deficiencies (adjusted hazard ratio, 17.5; 95% CI, 3.8-81.2). Our data provide evidence of clustering of the evaluated genetic thrombophilic defects in symptomatic factor V Leiden carriers and support the assumption that the clinical expression of factor V Leiden depends on clustering in a part of carriers. Blood Coagul Fibrinolysis 12:713-720 (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:713 / 720
页数:8
相关论文
共 50 条
  • [31] The factor V Leiden mutation and the risk of venous thromboembolism in gynecologic oncology patients
    Ravin, AJ
    Edwards, RP
    Krohn, MA
    Kelley, JR
    Christopherson, WA
    Roberts, JM
    OBSTETRICS AND GYNECOLOGY, 2002, 100 (06): : 1285 - 1289
  • [32] Lipoprotein(a), factor V Leiden mutation and the risk of future venous thromboembolism in women
    Danik, Jacqueline S.
    Glynn, Robert J.
    Buring, Julie E.
    Ricker, Paul M.
    CIRCULATION, 2007, 116 (16) : 819 - 819
  • [33] FACTOR V LEIDEN MUTATION INCREASES THE RISK FOR VENOUS THROMBOEMBOLISM IN PATIENTS WITH MALIGNANCY
    Pabinger, I.
    Dunkler, D.
    Vormittag, R.
    Ay, C.
    Marosi, C.
    Simanek, R.
    Zielinski, C. C.
    Mannhalter, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 212 - 212
  • [34] Factor V Leiden prevalence in venous thromboembolism patients
    Leroyer, C
    Mercier, B
    Escoffre, M
    Ferec, C
    Mottier, D
    CHEST, 1997, 111 (06) : 1603 - 1606
  • [35] Type of Combined Contraceptives, Factor V Leiden Mutation and Risk of Venous Thromboembolism
    Hugon-Rodin, Justine
    Horellou, Marie-Helene
    Conard, Jacqueline
    Gompel, Anne
    Plu-Bureau, Genevieve
    THROMBOSIS AND HAEMOSTASIS, 2018, 118 (05) : 922 - 928
  • [36] Factor V Leiden mutation increases the risk for venous thromboembolism in patients with malignancy
    Pabinger, I
    Dunkler, D.
    Vormittag, R.
    Ay, C.
    Marosi, C.
    Simanek, R.
    Zielinski, C.
    Mannhalter, C.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 427 - 427
  • [37] Additional risk factors for venous thromboembolism in carriers of FV Leiden
    Tosetto, A
    Missiaglia, E
    Martinelli, I
    De Stefano, V
    Rodeghiero, F
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 147 - 147
  • [38] The incidence of venous thromboembolism in asymptomatic carriers of the factor V leiden mutation:: A prospective cohort study
    Middeldorp, S
    Meinardi, JR
    Koopman, MMW
    van Pampus, ECM
    Hamulyák, K
    van der Meer, J
    Prins, MH
    Büller, HR
    THROMBOSIS AND HAEMOSTASIS, 1999, : 418 - 418
  • [39] A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism
    Middeldorp, S
    Meinardi, JR
    Koopman, MMW
    van Pampus, ECM
    Hamulyák, K
    van der Meer, J
    Prins, MH
    Büller, HR
    ANNALS OF INTERNAL MEDICINE, 2001, 135 (05) : 322 - 327
  • [40] The risk of pregnancy-related venous thromboembolism in double carriers of factor V leiden and prothrombin G20210A
    Battaglioli, T.
    De Stefano, V.
    Tormene, D.
    Valdre, L.
    Grandone, E.
    Tosetto, A.
    Martinelli, I.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 123 - 123